大学化学 >> 2022, Vol. 37 >> Issue (3): 2110094.doi: 10.3866/PKU.DXHX202110094

所属专题: 生物无机与大健康

今日化学 上一篇    下一篇

线粒体靶向铱(Ⅲ)配合物克服肿瘤耐药

熊凯, 陈禹(), 计亮年, 巢晖()   

  • 收稿日期:2021-10-29 录用日期:2021-11-15 发布日期:2021-12-29
  • 通讯作者: 陈禹,巢晖 E-mail:chenyu63@mail.sysu.edu.cn;ceschh@mail.sysu.edu.cn
  • 作者简介:Email: ceschh@mail.sysu.edu.cn (巢晖)
    Email: chenyu63@mail.sysu.edu.cn (陈禹)
  • 基金资助:
    国家自然科学基金(21778079);国家自然科学基金(21977126);广东省杰出青年基金(2021B1515020102);广州市珠江科技新星专项(201806010136)

Overcome Tumour Drug Resistance with Mitochondrial-Targeting Cyclometalated Iridium(Ⅲ) Complexes

Kai Xiong, Yu Chen(), Liangnian Ji, Hui Chao()   

  • Received:2021-10-29 Accepted:2021-11-15 Published:2021-12-29
  • Contact: Yu Chen,Hui Chao E-mail:chenyu63@mail.sysu.edu.cn;ceschh@mail.sysu.edu.cn

摘要:

以顺铂代表的金属铂类药物在临床抗肿瘤治疗取得了巨大的成功,但铂类药物的毒副作用和耐药性很大程度上限制了其临床使用范围及疗效。以结构稳定、具有独特三维立体构型的铱(Ⅲ)配合物为构筑单元,可以有效跳出传统铂类药物的局限。线粒体科学是当今化学、生命科学及分子医学最为活跃的交叉前沿研究领域之一。作为可预见的治疗靶点,线粒体靶向抗肿瘤试剂在克服肿瘤耐药、治疗肿瘤中具有十分突出的优势。本文中,结合铂类化疗药物耐药机制,同时以本课题组近年工作为基础,简要介绍具有线粒体靶向的环金属铱(Ⅲ)配合物克服肿瘤耐药研究进展。

关键词: 环金属铱(Ⅲ)配合物, 线粒体靶向, 顺铂, 肿瘤耐药

Abstract:

Despite the great success of platinum-based drugs in clinical cancer treatments, the side effects and drug resistance greatly limit their clinical application and curative effect. Possessing the stable structure and unique three-dimensional configuration, iridium (Ⅲ) complexes can effectively jump out of the limitations of traditional platinum-based drugs. On the other hand, mitochondrial science is one of the most active interdiscipline. As a predictable therapeutic target, mitochondrial-targeting antitumor agents have prominent advantages in overcoming tumour drug resistance. Herein, we introduce the mechanism of platinum chemotherapeutic drug resistance. Based on the recent research of our group, we also briefly summarize the research progress of mitochondrial-targeting iridium(Ⅲ) complexes to overcome the tumor drug resistance.

Key words: Cyclometalated iridium(Ⅲ) complexes, Mitochondrial targeting, Cisplatin, Tumour drug-resistant

MSC2000: 

  • G64